Johnson & Johnson Common Stock (JNJ)
Stock · NYSE · Health Care
$255.54as of 10/16/2026
Price chart
Active signals
JNJ Signal Track Record
How signals performed across all stocks →What JNJ's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 29 | +0.9% | 55% | September 18, 2026 |
| 200-Day Moving Average TouchActive now | 29 | -0.6% | 48% | June 27, 2025 |
| Bollinger Band Breakout | 25 | +2.1% | 72% | August 18, 2026 |
| Bollinger Band Breakdown | 22 | +0.0% | 50% | October 1, 2026 |
| Any 20-session window (baseline) | +0.6% | 55% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 138,200
- Website
- www.jnj.com/
Fundamentals
- 1-day range
- $252.62$262.45
- Market cap
- $619.30B
- P/E (trailing)
- 38.77
- P/E (forward)
- 21.64
- EPS (trailing)
- $6.59
- Dividend yield
- 3.12%
- Beta
- 0.20
- Avg. volume
- 7.09M
- Ex-dividend date
- November 24, 2026
- Dividend pay date
- December 8, 2026
How Johnson & Johnson Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 11, 2026 · via SEC EDGAR / Finnhub
Forecasts
22 analyst ratings
Johnson & Johnson Common Stock Competitors
Chosen by industry and closest market cap.
- JNJJohnson & Johnson Common Stock$255.56▲ 0.90%Market cap $619.30BP/E 38.77$184.66$281.07
- ABBVAbbVie Inc. Common Stock$285.42▲ 0.71%Market cap $430.95BP/E 79.39$190.75$285.4
- MRKMerck & Company Inc. Common Stock (new)$145.95▲ 0.52%Market cap $317.05BP/E 112.60$82.01$156.92
- NVSNovartis AG Common Stock$150.62▲ 0.16%Market cap $294.26BP/E 21.21$97.05$132.68
- AZNAstraZeneca PLC Ordinary Shares$165.41▼ 0.76%Market cap $249.78BP/E 24.19$11,404$15,730
- NVONovo Nordisk A/S Common Stock$38.83▼ 0.99%Market cap $203.55BP/E 9.74$224.25$409.95
- ABTAbbott Laboratories Common Stock$104.89▲ 0.20%Market cap $186.81BP/E 33.41$81.97$132.03
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| JNJ Johnson & Johnson Common Stock | $619.30B | 38.77 | $255.56 | ▲ 0.90% | $184.66$281.07 |
| ABBV AbbVie Inc. Common Stock | $430.95B | 79.39 | $285.42 | ▲ 0.71% | $190.75$285.4 |
| MRK Merck & Company Inc. Common Stock (new) | $317.05B | 112.60 | $145.95 | ▲ 0.52% | $82.01$156.92 |
| NVS Novartis AG Common Stock | $294.26B | 21.21 | $150.62 | ▲ 0.16% | $97.05$132.68 |
| AZN AstraZeneca PLC Ordinary Shares | $249.78B | 24.19 | $165.41 | ▼ 0.76% | $11,404$15,730 |
| NVO Novo Nordisk A/S Common Stock | $203.55B | 9.74 | $38.83 | ▼ 0.99% | $224.25$409.95 |
| ABT Abbott Laboratories Common Stock | $186.81B | 33.41 | $104.89 | ▲ 0.20% | $81.97$132.03 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $287benzinga · 10/16/2026
- How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?Yahoo · 10/11/2026
- Johnson & Johnson (NYSE:JNJ): Dividend Quality Makes It a Durable Income PickChartMill · 10/10/2026
- Banking Bellwethers Kick Off Earnings, Fed Chair's Speech In FocusSeekingAlpha · 10/10/2026
- 2 Dividend Stocks Worth Holding Forever (Including 1 Dividend King)Yahoo · 10/10/2026
- Why Is Everyone Ignoring Gilead Stock's High Cash Yield?Yahoo · 10/10/2026
- Estimates Keep Rising as Q3 Earnings Season Takes Center StageYahoo · 10/9/2026
- Coca-Cola (NYSE:KO) & Johnson & Johson (NYSE:JNJ): Buy Them For The Dividends, Says Jim CramerYahoo · 10/9/2026
- Friday's session: top gainers and losers in the dow jones indexChartMill · 10/9/2026
Insider Activity
Insider Actions →- Woods Eugene A. · September 8, 2026 · Grant136 @ $276.31
- Daniel E. Pinto · September 8, 2026 · Grant113 @ $276.31
- Marillyn A. Hewson · September 8, 2026 · Grant181 @ $276.31
- Timothy Schmid · September 2, 2026 · Option Exercise22.5K @ $151.41
- Timothy Schmid · September 2, 2026 · Option Exercise11.1K @ $131.94
- Timothy Schmid · September 2, 2026 · Sale22.5K @ $274.74
- Timothy Schmid · September 2, 2026 · Sale11.1K @ $274.74
- Jennifer L. Taubert · August 17, 2026 · Option Exercise15.0K @ $115.67
- Jennifer L. Taubert · August 17, 2026 · Sale15.0K @ $263.36
- Joaquin Duato · August 13, 2026 · Option Exercise123.3K @ $115.67
- Joaquin Duato · August 13, 2026 · Sale102.3K @ $261
- Joaquin Duato · August 13, 2026 · Sale21.0K @ $262
- Elizabeth Forminard · August 6, 2026 · Option Exercise9.3K @ $131.94
- Elizabeth Forminard · August 6, 2026 · Sale6.6K @ $255.93
- Elizabeth Forminard · August 6, 2026 · Sale9.3K @ $257.76
Institutional Ownership
March 31, 2026
- Total shares held
- 1.65B
- Total value held
- $389.05B
- Institutional holders
- 4586
- Unknown213.39M
- Unknown156.61M
- Unknown133.48M
- Unknown59.16M
- Unknown44.72M
- Unknown31.59M
- Unknown29.32M
- Unknown25.52M
- Unknown24.77M
- Unknown21.82M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Johnson & Johnson: Key Takeaways for Long-Term Investors
Recent coverage highlighted three takeaways for long‑term investors in Johnson & Johnson. The article notes the company's steady dividend yield of about 3.1% and its diversified healthcare portfolio. It also points to a relatively high price‑to‑earnings multiple, suggesting expectations of continued growth. These points are relevant as the stock trades near a long‑standing support level.
Johnson & Johnson: Key Takeaways for Long-Term Investors. Recent coverage highlighted three takeaways for long‑term investors in Johnson & Johnson. The article notes the company's steady dividend yield of about 3.1% and its diversified healthcare portfolio. It also points to a relatively high price‑to‑earnings multiple, suggesting expectations of continued growth. These points are relevant as the stock trades near a long‑standing support level.